

TRIAL DESIGN	Multi-centre, open label, blind-rated, effectiveness study of clozapine vs <b>TAU</b> Treatment as usual (oral antipsychotic, clinician's choice) for <b>12 weeks</b> in <b>50</b> children and young people with TRS ( <b>12-24 yrs old</b> )	
PRIMARY OUTCOME	Change in blind-rated <b>PANSS</b> scores at 12 weeks	
SECONDARY OUTCOMES	<ul> <li>Blind-rated CGI</li> <li>Patient-rated outcomes</li> <li>Quality of life</li> </ul>	<ul> <li>Adverse effects</li> <li>Treatment adherence</li> <li>Service use</li> </ul>